- Home
- IBIO
IBIO
iBio Inc.
as 11-15-2024 4:00pm EST
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 23.4M | IPO Year: | N/A |
| Target Price: | $4.30 | AVG Volume (30 days): | 97.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $6.20 | Next Earning Date: | 11-12-2024 |
| Revenue: | $175,000 | Revenue Growth: | 250.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest iBio Inc. News
IBIO Breaking Stock News: Dive into IBIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
iBio Reports Fiscal First Quarter 2025 Financial Results
GlobeNewswire
a month ago
iBio and AstralBio Provide Update on Myostatin Program for Obesity
GlobeNewswire
2 months ago
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
2 months ago
iBio to Participate in Upcoming Investor Conferences
GlobeNewswire
3 months ago
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
GlobeNewswire
5 months ago
iBio Closes Sale of Manufacturing Facility in Texas
GlobeNewswire
6 months ago
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
8 months ago
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
Compare IBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IBIO iBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.